GlassScriptPhysician profile
Stephanie D Davis
NPI 1184928921
$4,057.54
in general payments reported to CMS, 2019-2025
39 companies · $895 in 2025
The $895 reported for 2025 was more than what 85% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $289 · 2022: $634 · 2023: $1,164 · 2024: $1,075 · 2025: $895.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,133.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $444.22 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $402.17 | 2022-2023 | Arexvy, Bexsero, Shingrix |
| Abbvie INC. | $347.98 | 2021-2025 | |
| Genzyme Corporation | $344.06 | 2024 | |
| Lilly USA, LLC | $241.23 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Dexcom, INC. | $206.82 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Astrazeneca Pharmaceuticals LP | $149.30 | 2022-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $149.23 | 2025 | Voquezna |
| Pfizer INC. | $134.29 | 2023-2025 | |
| Mylan Specialty L.P. | $124.99 | 2024 | Yupelri |
| Kyowa Kirin, INC. | $121.86 | 2025 | |
| Gilead Sciences, INC. | $116.15 | 2025 | Epclusa |
| Axsome Therapeutics, INC. | $112.12 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $111.94 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.22 | 2021-2024 | Jardiance |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $90.93 | 2024 | Rexulti |
| Edwards Lifesciences Corporation | $79.91 | 2022-2023 | Sapien 3 Ultra Resilia |
| Exact Sciences Corporation | $72.69 | 2024-2025 | Cologuard Collection Kit |
| Radius Health, INC. | $69.08 | 2023-2024 | Tymlos |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.26 | 2023 | |
| Jazz Pharmaceuticals INC. | $62.50 | 2022 | |
| Biogen, INC. | $61.43 | 2024 | |
| Lucid Diagnostics INC. | $53.01 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $49.19 | 2021-2022 | |
| Abbott Laboratories | $41.10 | 2021-2023 | Freestyle Libre 3 |
| Ibsa Pharma INC. | $32.97 | 2021-2025 | Licart, Flector, Tirosint |
| Sanofi Pasteur INC. | $28.21 | 2022 | |
| Seqirus USA INC | $26.96 | 2023-2025 | Flucelvax, Fluad, Flucelvax Quadrivalent |
| Corium, LLC | $26.49 | 2023 | Azstarys |
| Medtronic, INC. | $26.42 | 2025 | Symplicity G3 |
| Alkermes, INC. | $24.93 | 2024 | Vivitrol |
| Alnylam Pharmaceuticals INC. | $21.32 | 2025 | Givlaari |
| Biohaven Pharmaceutical Holding Company LTD. | $18.93 | 2022 | |
| Tolmar, INC. | $17.50 | 2023 | |
| Azurity Pharmaceuticals, INC. | $17.11 | 2023 | Horizant |
| Merck Sharp & Dohme LLC | $15.28 | 2025 | Capvaxive, Vaxelis, Gardasil 9 |
| Cranial Technologies, INC | $14.87 | 2023 | Doc Band |
| Idorsia Pharmaceuticals US INC | $14.20 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $13.67 | 2023 | Xelstrym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephanie Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.